Literature DB >> 7387923

The in vitro production of prostanoids by the human cervix during pregnancy: preliminary observations.

D A Ellwood, M D Mitchell, A B Anderson, A C Turnbull.   

Abstract

The ability of the pregnant human cervix to produce prostanoids has been studied using an in vitro superfusion technique. Tissues obtained from four patients during the first trimester of pregnancy produced prostaglandin E (PGE), prostaglandin F (PGF), 13,14-dihydro-15-oxo-prostaglandin F (PGFM) and 6-oxo-prostaglandin F1 alpha (6-oxo-PGF1 alpha). Production of thromboxane B2 (TXB2) was minimal. Preliminary studies using tissue taken at Caesarean hysterectomy during the last trimester of pregnancy indicate that the cervix may show increased prostanoid production during active dilatation. The implications of these observations for an involvement of prostanoids in cervical softening during human parturition are discussed.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7387923     DOI: 10.1111/j.1471-0528.1980.tb04520.x

Source DB:  PubMed          Journal:  Br J Obstet Gynaecol        ISSN: 0306-5456


  3 in total

1.  The frequency and clinical significance of intra-amniotic infection and/or inflammation in women with placenta previa and vaginal bleeding: an unexpected observation.

Authors:  Ichchha Madan; Roberto Romero; Juan Pedro Kusanovic; Pooja Mittal; Tinnakorn Chaiworapongsa; Zhong Dong; Shali Mazaki-Tovi; Edi Vaisbuch; Zeynep Alpay Savasan; Lami Yeo; Chong Jai Kim; Sonia S Hassan
Journal:  J Perinat Med       Date:  2010-05       Impact factor: 1.901

2.  Suppression of natural cell-mediated cytotoxicity in man by maternal and neonatal serum.

Authors:  D S Barrett; L S Rayfield; L Brent
Journal:  Clin Exp Immunol       Date:  1982-03       Impact factor: 4.330

3.  Studies on human uterine cervix and rat uterus using S-, X- and Q-band electron-spin-resonance spectroscopy.

Authors:  A Tomasi; C Benedetto; M Nilges; T F Slater; H M Swartz; M C Symons
Journal:  Biochem J       Date:  1984-12-01       Impact factor: 3.857

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.